News | September 17, 2024
Panacea Biotec and Sanofi reached settlement agreement for Shan6
Sanofi would not manufacture or market any product which infringes the amended claims of Panacea patent, IN272351
Sanofi would not manufacture or market any product which infringes the amended claims of Panacea patent, IN272351
He has been associated with Caplin Steriles Ltd., Mylan Laboratories Ltd., Caplin Point Laboratories Ltd., Strides Arcolab Ltd. and Novartis Vaccines and Diagnostics
This validation aligns with Piramal Pharma's core purpose of 'Doing Well and Doing Good,'
Target identification will commence on 17 September 2024, following the timeline provided in the campaign guidelines
The award is for development of Nafithromycin, which is the first ever multi-drug resistant pathogen active respiratory antibiotic for the treatment of Community-Acquired Bacterial Pneumonia
India's bio economy has experienced remarkable growth, skyrocketing from US $10 billion in 2014 to over $130 billion in 2024, with projections to reach $300 billion by 2030
Lasa Supergenerics Limited has been granted patent for an invention “Processes for Preparation and Purification of 5-Chloro-2-Nitroaniline
The acquisition is based on an enterprise value of Rs. 1,660 crore
The company will now seek final approval from NCLT, Mumbai Bench, and upon its receipt, OneSource will proceed to seek listing approvals from the BSE and NSE
The sANDA was submitted as “Prior Approval Supplement” for addition of an alternate drug product manufacturing, labeling, packaging, and testing facility
Subscribe To Our Newsletter & Stay Updated
